HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Sutro Biopharma (NASDAQ:STRO) and maintained a price target of $12.
October 11, 2024 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Sutro Biopharma and maintained a price target of $12, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $12 price target by HC Wainwright & Co. suggests positive sentiment and confidence in Sutro Biopharma's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100